Cannabis was the largest of Canopy Growth Corp’s 2 reported lines in fiscal 2026, at $213.94M — 75% of $284.60M.
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|
| Canada Cannabis | $195.45M | — | — | — | ||||
| Cannabis | — | $191.68M | $186.73M | $213.94M | ||||
| Rest-Of-World Cannabis | — | — | — | — | ||||
| Storz Bickel | $64.85M | — | $82.27M | $70.66M | ||||
| Canadian Recreational Cannabis Net Revenue | — | — | — | — | ||||
| Consumer Products & Other | — | — | — | — | ||||
| International Markets Cannabis | $38.95M | — | — | — | ||||
| Canadian Medical Cannabis Net Revenue | — | — | — | — | ||||
| Recreational Cannabis Revenue | — | — | — | — | ||||
| Biosteel | — | — | — | — | ||||
| This Works | $26.03M | $21.26M | — | — | ||||
| Other Consumer Products | — | — | — | — | ||||
| International & Other Revenue | — | — | — | — | ||||
| Other | $7.99M | $4.74M | — | — | ||||
| Ancillary Cannabis Revenues | $6.06M | $5.02M | — | — | ||||
| Medical Cannabis Revenue | — | — | — | — | ||||
| Total | $339.31M | $222.70M | $269.00M | $284.60M |
In fiscal 2026, which ended March 31, 2026, the 2 segments Canopy Growth Corp reported in this breakdown added up to $284.60M. That was up 5.8% from $269.00M in fiscal 2025. Cannabis was the largest segment, at $213.94M or 75.2% of the total, followed by Storz Bickel ($70.66M, 24.8%).
Compared with fiscal 2025, Cannabis grew the fastest, rising 14.6% to $213.94M. Storz Bickel fell the most, down 14.1% to $70.66M.
Cannabis was first reported as a separate segment in fiscal 2024. The table also keeps 14 segments that Canopy Growth Corp no longer reports, so earlier years can still be read on their original basis; use "Show 14 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2019 to 2026, as reported in Canopy Growth Corp's annual filings.
Canadian Adult-Use Cannabis was the largest of Canopy Growth Corp’s 4 reported lines in fiscal 2026, at $94.47M — 33% of $284.60M.
| Product and Service | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|
| Canadian Adult-Use Cannabis | $133.59M | $92.80M | $78.83M | $94.47M |
| Canadian Medical Cannabis | $61.86M | $66.36M | $77.03M | $90.82M |
| Storz Bickel | $64.85M | — | $82.27M | $70.66M |
| International Markets Cannabis | $38.95M | $32.52M | $30.87M | $28.65M |
| This Work | $26.03M | $21.26M | — | — |
| Other | $7.99M | $4.74M | — | — |
| Total | $333.25M | $217.68M | $269.00M | $284.60M |
In fiscal 2026, which ended March 31, 2026, the 4 revenue lines Canopy Growth Corp reported in this breakdown added up to $284.60M. That was up 5.8% from $269.00M in fiscal 2025. Canadian Adult-Use Cannabis was the largest revenue line, at $94.47M or 33.2% of the total, followed by Canadian Medical Cannabis ($90.82M, 31.9%) and Storz Bickel ($70.66M, 24.8%). Together, the two largest revenue lines made up 65.1% of this total.
Compared with fiscal 2025, Canadian Adult-Use Cannabis grew the fastest, rising 19.8% to $94.47M. Storz Bickel fell the most, down 14.1% to $70.66M.
The table also keeps 2 revenue lines that Canopy Growth Corp no longer reports, so earlier years can still be read on their original basis; use "Show 2 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2023 to 2026, as reported in Canopy Growth Corp's annual filings.
Canada was the largest of Canopy Growth Corp’s 3 reported lines in fiscal 2026, at $186.09M — 84% of $222.53M.
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|
| Canada | $201.42M | $162.71M | $155.91M | $186.09M | |||
| Germany | — | $52.19M | $59.90M | — | |||
| United States | $36.43M | — | $35.99M | $28.27M | |||
| Other | $46.70M | — | $17.19M | $8.17M | |||
| Total | $284.55M | $214.91M | $269.00M | $222.53M |
In fiscal 2026, which ended March 31, 2026, the 3 regions Canopy Growth Corp reported in this breakdown added up to $222.53M. That is less than the $284.60M in its breakdown by segment, so these regions do not account for all of its revenue that year. Canada was the largest region, at $186.09M or 83.6% of the total, followed by United States ($28.27M, 12.7%) and Other ($8.17M, 3.7%). Together, the two largest regions made up 96.3% of this total.
Compared with fiscal 2025, Canada grew the fastest, rising 19.4% to $186.09M. Other fell the most, down 52.5% to $8.17M. Because regions were added or dropped between the two years, part of this reflects how Canopy Growth Corp regrouped its reporting.
The table also keeps 1 region that Canopy Growth Corp no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers 7 fiscal years between 2019 and 2026, as reported in Canopy Growth Corp's annual filings.
Canopy Growth Corp (CGC) breaks its revenue down by segment, revenue line and region. In fiscal 2026, its largest segment was Cannabis, with $213.94M or 75.2% of the total, followed by Storz Bickel at $70.66M (24.8%).
Cannabis was Canopy Growth Corp's largest segment in fiscal 2026, with $213.94M in revenue, 75.2% of the $284.60M reported across its 2 segments.
Canadian Adult-Use Cannabis was Canopy Growth Corp's largest revenue line in fiscal 2026, with $94.47M in revenue, 33.2% of the $284.60M reported across its 4 revenue lines.
Canada was Canopy Growth Corp's largest region in fiscal 2026, with $186.09M in revenue, 83.6% of the $222.53M reported across its 3 regions.
Of the Canopy Growth Corp segments reported in both fiscal 2025 and fiscal 2026, and making up at least 2% of the total, Cannabis grew the fastest, rising 14.6% from $186.73M to $213.94M.
Every figure is taken from Canopy Growth Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2019 to 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.